Latest news with #JustinLee
Korea Herald
3 hours ago
- Business
- Korea Herald
Novogene Certified for Olink® Services Across Multiple Labs; Expands Proteomics Portfolio with Olink® Reveal
SINGAPORE, June 5, 2025 /PRNewswire/ -- Novogene, a global leader in multi-omics solutions, is proud to announce its designation as an Olink ® Certified Service Provider (CSP) across multiple laboratories worldwide. This milestone positions Novogene among the first globally to offer high-throughput, high-quality protein biomarker discovery services using Olink's leading proteomics platforms. This multi-site certification validates Novogene's capabilities to execute Olink ® workflows with exceptional precision, consistency, and scalability across global labs—enabling advanced translational research and precision medicine for pharmaceutical, biotech, and academic partners. Novogene has broadened its suite of high-plex proteomics, with the addition of Olink ® Reveal. Olink ® Reveal enables the quantification of ~1,000 curated human proteins, including 537 inflammation markers, spanning 96% of immune response pathways and 64% of all Reactome pathways. The assay features validated, biologically relevant content enriched with cis-pQTLs—ideal for proteogenomic applications—allowing researchers to both broadly screen the proteome and deeply investigate inflammation biology. "Being certified as an Olink ® CSP across multiple Novogene labs underscores our commitment to delivering high-quality, globally harmonized data. With Olink ® Reveal offering deep insights into inflammatory biology, we empower researchers to accelerate biomarker discovery, translational research, and precision medicine. This recognition further enhances Novogene's leadership in comprehensive multi-omics solutions." said Justin Lee, Novogene VP of Global Marketing. "We are extremely excited to see Olink ® proteomics solutions being adopted by Novogene, a global provider of multi-omics solutions," said Andrea Ballagi, Olink VP of Sales and Marketing. "As part of a worldwide network of Olink ® Certified Service Providers, Novogene is well-positioned to enable scientists around the world to advance biomarker research and contribute to a healthier, cleaner and safer world". As part of the Olink ® global CSP network, Novogene is committed to deliver reproducible, high-quality data to empower the exploration of disease mechanisms, therapeutic targets, and novel biomarkers. About Novogene Novogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation.
Yahoo
8 hours ago
- Business
- Yahoo
Novogene Certified for Olink® Services Across Multiple Labs; Expands Proteomics Portfolio with Olink® Reveal
SINGAPORE, June 5, 2025 /PRNewswire/ -- Novogene, a global leader in multi-omics solutions, is proud to announce its designation as an Olink® Certified Service Provider (CSP) across multiple laboratories worldwide. This milestone positions Novogene among the first globally to offer high-throughput, high-quality protein biomarker discovery services using Olink's leading proteomics platforms. This multi-site certification validates Novogene's capabilities to execute Olink® workflows with exceptional precision, consistency, and scalability across global labs—enabling advanced translational research and precision medicine for pharmaceutical, biotech, and academic partners. Novogene has broadened its suite of high-plex proteomics, with the addition of Olink® Reveal. Olink® Reveal enables the quantification of ~1,000 curated human proteins, including 537 inflammation markers, spanning 96% of immune response pathways and 64% of all Reactome pathways. The assay features validated, biologically relevant content enriched with cis-pQTLs—ideal for proteogenomic applications—allowing researchers to both broadly screen the proteome and deeply investigate inflammation biology. "Being certified as an Olink® CSP across multiple Novogene labs underscores our commitment to delivering high-quality, globally harmonized data. With Olink® Reveal offering deep insights into inflammatory biology, we empower researchers to accelerate biomarker discovery, translational research, and precision medicine. This recognition further enhances Novogene's leadership in comprehensive multi-omics solutions." said Justin Lee, Novogene VP of Global Marketing. "We are extremely excited to see Olink® proteomics solutions being adopted by Novogene, a global provider of multi-omics solutions," said Andrea Ballagi, Olink VP of Sales and Marketing. "As part of a worldwide network of Olink® Certified Service Providers, Novogene is well-positioned to enable scientists around the world to advance biomarker research and contribute to a healthier, cleaner and safer world". As part of the Olink® global CSP network, Novogene is committed to deliver reproducible, high-quality data to empower the exploration of disease mechanisms, therapeutic targets, and novel biomarkers. About NovogeneNovogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation. CONTACT: Novogene AMEA (APAC, Middle-East & Africa)marketing_amea@ View original content: SOURCE Novogene
Yahoo
12-05-2025
- Business
- Yahoo
Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Siren Biotechnology Inc., pioneers of Universal AAV Immuno-Gene Therapy for Cancer, today announced that it will present new scientific data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 13–17 in New Orleans, LA. The company's presentations include one oral session and two poster presentations that highlight recent scientific advances and underscore the therapeutic potential of Siren's AAV-based immuno-gene therapy platform across solid tumor indications. Presentation details: Oral Presentation: SRN-101 Universal AAV Gene Therapy for Solid Tumors. Dr. Nicole K. Paulk, CEO, Founder, President, Siren Biotechnology May 17, 2025 | 8:00am CST Poster Presentations: Vectorized Interferons Provide a Robust and Sustained Transcriptional Response Over Traditional Non-Vectorized Recombinant Cytokine Therapies in Human High-Grade Glioma Cells. Justin Lee, BS, Preclinical Associate Scientist May 14, 2025 | 5:30 – 7:00pm CST Identification of Pharmacologically Relevant Species for IND-Enabling Toxicology Studies by Deep Comparative Transcriptomic Profiling of PBMCs Treated with Recombinant Human Payloads. Christopher Lovejoy, MS, Preclinical Associate Scientist May 14, 2025 |5:30 – 7:00pm CST 'We're excited to share our latest data with the scientific community at ASGCT, which remains the most prestigious venue for showcasing gene therapy innovations,' said Dr. Nicole K. Paulk, PhD, Siren Biotechnology's CEO and Founder. 'These presentations reflect our continued progress advancing our Universal AAV Immuno-Gene Therapy Platform and our commitment to developing transformative therapies to treat solid tumor cancers.' About Siren Biotechnology Headquartered in San Francisco, CA, Siren Biotechnology is sounding the alarm against cancer. We are the pioneers of Universal AAV Immuno-Gene Therapy, which combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single modality which we believe will redefine how we destroy tumor cells and elicit anti-tumor immunity. Our vision is for Universal AAV Immuno-Gene Therapy to become the standard of care for any solid tumor cancer. To learn more, visit and follow us on LinkedIn, Twitter, Facebook and Instagram. Universal AAV Immuno-Gene Therapy for Cancer. It's Here. CONTACT: Contact Akela Kuwahara press@
Yahoo
12-05-2025
- Business
- Yahoo
Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Siren Biotechnology Inc., pioneers of Universal AAV Immuno-Gene Therapy for Cancer, today announced that it will present new scientific data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 13–17 in New Orleans, LA. The company's presentations include one oral session and two poster presentations that highlight recent scientific advances and underscore the therapeutic potential of Siren's AAV-based immuno-gene therapy platform across solid tumor indications. Presentation details: Oral Presentation: SRN-101 Universal AAV Gene Therapy for Solid Tumors. Dr. Nicole K. Paulk, CEO, Founder, President, Siren Biotechnology May 17, 2025 | 8:00am CST Poster Presentations: Vectorized Interferons Provide a Robust and Sustained Transcriptional Response Over Traditional Non-Vectorized Recombinant Cytokine Therapies in Human High-Grade Glioma Cells. Justin Lee, BS, Preclinical Associate Scientist May 14, 2025 | 5:30 – 7:00pm CST Identification of Pharmacologically Relevant Species for IND-Enabling Toxicology Studies by Deep Comparative Transcriptomic Profiling of PBMCs Treated with Recombinant Human Payloads. Christopher Lovejoy, MS, Preclinical Associate Scientist May 14, 2025 |5:30 – 7:00pm CST 'We're excited to share our latest data with the scientific community at ASGCT, which remains the most prestigious venue for showcasing gene therapy innovations,' said Dr. Nicole K. Paulk, PhD, Siren Biotechnology's CEO and Founder. 'These presentations reflect our continued progress advancing our Universal AAV Immuno-Gene Therapy Platform and our commitment to developing transformative therapies to treat solid tumor cancers.' About Siren Biotechnology Headquartered in San Francisco, CA, Siren Biotechnology is sounding the alarm against cancer. We are the pioneers of Universal AAV Immuno-Gene Therapy, which combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single modality which we believe will redefine how we destroy tumor cells and elicit anti-tumor immunity. Our vision is for Universal AAV Immuno-Gene Therapy to become the standard of care for any solid tumor cancer. To learn more, visit and follow us on LinkedIn, Twitter, Facebook and Instagram. Universal AAV Immuno-Gene Therapy for Cancer. It's Here. CONTACT: Contact Akela Kuwahara press@
Yahoo
09-05-2025
- General
- Yahoo
Valedictorian makes school history earning degree before diploma
A Dayton high school valedictorian made school history, earning his associate's degree before receiving his high school diploma. [DOWNLOAD: Free WHIO-TV News app for alerts as news breaks] Thurgood Marshall STEM High School Valedictorian Justin Lee is the first student from the school to reach this academic achievement, a spokesperson for the Dayton Public School District said in a media release. Lee will graduate with an associate's degree in psychology from Sinclair Community College this month through the district's College Credit Plus program. TRENDING STORIES: Conclave votes: First American pope chosen in history; Cardinal Robert Prevost (live updates) High school lacrosse player dies from injury during game Police warn of 'motion picture money' being used at area garage sales The College Credit Plus program offers students the opportunity to take college-level courses at no cost. The program was designed to help students save time and money as they prepare for college and careers after graduation. The college credits students earn in the program can be transferred to any Ohio public college or university, according to the release. Private and out-of-state institutions often accept these credits as well. 'Justin's accomplishment is nothing short of extraordinary. He represents the very best of what our students can achieve when given access to rigorous academic opportunities and strong support systems,' said Superintendent of Dayton Public Schools Dr. David Lawrence. Lee will attend the University of Dayton on a full-ride Flyer Promise scholarship this fall. He plans to major in psychology, according to the release. [SIGN UP: WHIO-TV Daily Headlines Newsletter]
